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A B S T R A C T
Because cartilage lacks nerves, blood vessels, and lymphatic vessels, it is thought to contain factors that inhibit
the growth and development of those tissues. Chondroitin sulfate proteoglycans (CSPGs) are a major
extracellular component in cartilage. CSPGs contribute to joint ﬂexibility and regulate extracellular signaling
via their attached glycosaminoglycan, chondroitin sulfate (CS). CS and CSPG inhibit axonal regeneration;
however, their role in blood vessel formation is largely unknown. To clarify the function of CSPG in blood vessel
formation, we tested salmon nasal cartilage proteoglycan (PG), a member of the aggrecan family of CSPG, for
endothelial capillary-like tube formation. Treatment with salmon PG inhibited endothelial cell adhesion and in
vitro tube formation. The anti-angiogenic activity was derived from CS in the salmon PG but not the core
protein. Salmon PG also reduced matrix metalloproteinase expression and inhibited angiogenesis in the chick
chorioallantoic membrane. All of these data support an anti-angiogenic role for CSPG in cartilage.
1. Introduction
Chondroitin sulfate proteoglycans (CSPGs) are major components
of cartilage, together with collagens and hyaluronan. Proteoglycan (PG)
is a glycoprotein comprising a single core protein and attached
glycosaminoglycan (GAG) polysaccharides. The GAG of CSPGs is
mainly chondroitin sulfate (CS). Although CSPG is a major PG in
cartilage, other PGs such as heparan sulfate PGs (HSPGs), dermatan
sulfate PGs, and keratin sulfate PGs (KSPGs) are widely distributed in
the cell surface and the extracellular matrix (ECM) of animal tissues
[1].
CSPG and CS are major inhibitors of neuronal migration [2,3].
Cartilage lacks neurons, blood vessels, and lymphatic vessels, which led
to the hypothesis that cartilage contains substances that inhibit the
growth of those tissues. Therefore, CSPG and CS are expected to have
an inhibitory eﬀect on blood vessel formation. Indeed, loss of PG in
osteoarthritic (OA) cartilage is associated with loss of resistance to
vascular invasion [4]. Human intervertebral disc aggrecan was shown
to inhibit endothelial cell migration [5]. Inhibition of endothelial cell
adhesion and migration would inhibit tubulogenesis. Although the
anti-migration activity of aggrecan was attributed to its CS moiety, CS
alone showed both anti-angiogenic [6] and pro-angiogenic activities
[7]. Moreover, treatment with chondroitinase, which is a speciﬁc GAG
lyase, inhibits endothelial cell proliferation and angiogenesis, indicat-
ing that endogenous CS in endothelial cells is essential for angiogenesis
[8]. Thus, it remains unclear whether CSPGs play an inhibitory role in
blood vessel formation.
To clarify the role of CSPG in blood vessel formation, we aimed to
identify eﬀects of salmon nasal cartilage PG on angiogenesis. The
conventional procedure for extraction of PG uses 4 M guanidine
hydrochloride (GdnHCl) [9]. Recently, a simple, low-toxicity procedure
for extraction of PG from salmon nasal cartilage was developed using
acetic acid [10]. Our previous report showed that the major PG in this
salmon PG fraction is from the aggrecan family of CSPGs [11]. Based
on the cDNA sequence, globular domains G1, G2, and G3 are conserved
between salmon and mammalian aggrecan. However, the core protein
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of acetic acid-extracted salmon PG is partially fragmented compared to
that of GdnHCl-extracted salmon PG [12]. Although the acetic acid-
extracted PG is the fragmented CSPG fraction, it retains various
biological activities and is the only commercially available PG for
pharmacological use [13–17]. In this study, we show that salmon PG
reduces the tube-like formation of vascular endothelial cells. The anti-
angiogenic activity of salmon PG was derived from CS. In addition,
salmon PG reduced matrix metalloproteinase (MMP) expression in
endothelial cells. Our results support an anti-angiogenic function of
CSPG and CS.
2. Materials and methods
2.1. Cell culture
The immortalized human umbilical vein endothelial cell line
EA.hy926 was obtained from ATCC (CRL-2922, Manassas, VA, USA).
The cells were maintained in Medium 199 (Life Technologies Japan,
Tokyo, Japan) supplied with 10% fetal bovine serum (FBS) (GE
Healthcare Japan, Tokyo, Japan) and penicillin/streptomycin (Life
Technologies Japan). The cells were incubated at 37 °C in a humidiﬁed
atmosphere containing 5% CO2.
2.2. Puriﬁcation of proteoglycan
Acetic acid-extracted salmon nasal cartilage PG was purchased
from Ichimaru Pharcos Co., Ltd. (Gifu, Japan). The PG was repuriﬁed
by ion-exchange chromatography as described previously with minor
modiﬁcations [12]. Brieﬂy, PG was dissolved in 7 M urea in 50 mM
Tris-HCl buﬀer (pH 7.5) and applied to a column (2.5 cm×10 cm) ﬁlled
with DEAE-sephacel (GE Healthcare Japan) at a ﬂow rate of 0.5 mL/
min. The column was washed with ﬁve column volumes of 7 M urea in
50 mM Tris–HCl buﬀer (pH 7.5) and eluted with ﬁve column volumes
of 0.0–1.0 M NaCl in a linear gradient, and 5-mL fractions were
collected. Uronic acid (UA)-rich fractions were pooled, dialyzed against
pure water, and concentrated by Speedvac (Thermo Fisher Scientiﬁc,
Waltham, MA, USA). The PG was sterilized with a 0.2-μm ﬁlter and
stored at −80 °C until use. UA and protein contents in the puriﬁed PG
were determined by the carbazole sulfuric acid method [18] and using
Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA, USA), respec-
tively. In this study, we used UA as a unit of PG and CS. The
composition of CS in salmon PG was approximately 14.4% ΔDi-0S
[glucuronic acid (GlcUA)- N-acetylgalactosamine (GalNAc)], 27.0%
ΔDi-4S [GlcUA-GalNAc(4S)], 57.8% ΔDi-6S [GlcUA-GalNAc(6S)],
0.8% ΔDi-SD [GlcUA(2S)-GalNAc(6S)], and 0.0% ΔDi-SE [GlcUA-
GalNAc(4S, 6S)].
2.3. Cell viability test
EA.hy926 cells were seeded in a 96-well microplate at 16,000 cells/
cm2 and incubated in the culture medium at 37 °C for 24 h. After
washing with phosphate-buﬀered saline (PBS), 0.1 mL of serum-free
medium containing various concentrations of PG was added to the
wells. After 24 or 48 h of incubation, 0.01 mL of WST-8 reagent (Cell
count reagent SF, Nacalai Tesque Inc., Kyoto, Japan) was added to each
well. The plate was incubated at 37 °C for 1 h. The absorbance at
450 nm of each well was measured using a Benchmark microplate
reader (Bio-Rad).
2.4. Cell adhesion assay
A 96-well culture plate was incubated with 2 μg/well human plasma
ﬁbronectin (Life Technologies Japan) in PBS at 4 °C overnight. To
block the uncoated area, the ﬁbronectin-coated plate was incubated
with 0.5% bovine serum albumin (BSA) (Sigma-Aldrich Japan, Tokyo,
Japan) in PBS at 37 °C for 30 min and then washed with PBS three
times. Thereafter, various amounts of PG in PBS (100 μL) were added
to the well, and the plate was incubated at 37 °C for 30 min and then
rinsed with PBS three times. Single-cell suspensions in serum-free
media (20,000 cells/100 μL/well) were added to the well and incubated
at 37 °C for 1 h. After incubation, the plate was vortexed on a plate
shaker and washed with PBS three times to remove unattached cells.
The numbers of attached cells were estimated by crystal violet assay.
The crystal violet solution (0.2% in 25% methanol) was added to the
well and incubated for 10 min. The plate was washed with water and
then dried. Sodium dodecyl sulfate solution (1%) was added to the well
to solubilize the stain. The number of cells was estimated by the
absorbance at 570 nm of each well.
2.5. Enzymatic digestion of salmon PG
The PG (3 mg/mL) was incubated with 1 mg/mL Actinase E (Kaken
Pharmaceutical Co. Ltd., Tokyo, Japan) for 16 h at 50 °C in 100 mM
Tris–HCl (pH 8.0) and 10 mM CaCl2. The reaction was terminated by
boiling for 3 min. The PG (3 mg/mL) was incubated with 250 mU/mL
protease-free chondroitinase ABC (C3667, Sigma-Aldrich Japan) for
16 h at 37 °C in 50 mM Tris–HCl (pH 8.0), 60 mM CH3COONa, and
0.02% BSA. The reaction was terminated by boiling for 3 min. To
remove digested CS oligosaccharides, the reaction was puriﬁed by
ultraﬁltration with Amicon Ultracel 30 kDa ﬁlters (Merck Millipore
Ltd., Darmstadt, Germany). All reactions were sterilized with a Coaster
Spin-X centrifuge ﬁlter unit (Corning Japan K.K., Tokyo, Japan). The
eﬃciency of enzymatic digestion was evaluated using a combination of
agarose gel electrophoresis and Stains-All staining (Sigma-Aldrich
Japan).
2.6. In vitro tube formation
The in vitro angiogenesis assay was performed as described by
Arnaoutova and Kleinman with minor modiﬁcations [19]. Brieﬂy,
50 μL of Basement Membrane Extract (BME, Trevigen Inc.,
Gaithersburg, MD, USA) was added to a 96-well plate on ice. The
plate was incubated for 30 min at 37 °C for gelling. EA.hy926 cells
(5000 cells) in 100 μL of serum-free media with or without PG were
added to the plate and cultured on the BME gel for 16–20 h. In some
experiments, the enzyme-digested PG (mentioned above), CS4S
(400655, Seikagaku Corp., Tokyo, Japan), or CS6S (400675,
Seikagaku Corp.) was used instead of PG. The composition of CS4S
was 1.7% ΔDi-0S, 74.1% ΔDi-4S, 23.0% ΔDi-6S, 1.0% ΔDi-SD, and
0.2% ΔDi-SE and that of CS6S was 1.9% ΔDi-0S, 12.7% ΔDi-4S, 75.0%
ΔDi-6S, 7.6% ΔDi-SD, and 2.8% ΔDi-SE. Photographs were taken using
a digital camera (E-330, Olympus Corp., Tokyo, Japan) attached to an
Olympus CKX41 microscope. Tube formation was analyzed with
ImageJ [20] using the Angiogenesis Analyzer Plug-in [21].
2.7. Real-time quantitative PCR and gelatin zymography
Conﬂuent cells were incubated in media supplemented with 0.5%
FBS and 0.5% BSA with or without PG for 24 h. Culture supernatants
were used for gelatin zymography to analyze MMP expression. Gelatin
zymography was performed as described previously [22]. To analyze
the mRNA level, total RNA was isolated from the cells using an RNeasy
mini kit (QIAGEN Japan, Tokyo, Japan) according to manufacturer's
procedure. To generate cDNA, reverse transcription was performed
with 1 μg of RNA using a High-Capacity cDNA Reverse Transcription
Kit (Life Technologies Japan). Quantitative real-time PCR was per-
formed using a StepOnePlus Real-time PCR system (Life Technologies
Japan). The reaction mixtures contained each cDNA, FastStart
Universal Probe Master [ROX] (Roche Diagnostics GmbH,
Mannheim, Germany), and TaqMan Probes (Life Technologies
Japan) for each gene (Table 1). The reaction was performed for 40
cycles of 95 °C for 10 s and 60 °C for 30 s followed by 95 °C for 10 min.
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The expression level was analyzed by the comparative Ct method and
normalized to that of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
2.8. Chick chorioallantoic membrane (CAM) assay
Fertilized white leghorn chicken eggs (Hasegawa Natural Farm,
Aomori, Japan) were incubated in a humidiﬁed incubator at 38 °C. On
day 2 of incubation, a circular window was opened following removal of
3 ml of albumen by using a needle. The window was sealed with a
cellophane tape, and the eggs were returned to the incubator. On day 7,
silicon rings (6.8 mm inner diameter) were placed on the CAM. Then,
50 μl of PG in PBS was applied into the ring. After 48 h of incubation,
whipping cream was injected under the CAM to facilitate visualization
of blood vessels. The density of the vessel area in the ring was
quantiﬁed using AngioTool software [23].
3. Results
3.1. Eﬀects of salmon PG on endothelial cell viability and adhesion
Endothelial cells were cultured with salmon PG to examine the
eﬀect of CSPG on cell growth and viability. There were no signiﬁcant
diﬀerences between the control and each concentration of PG (0–1 mg/
mL) treatment after 24 h (Fig. 1A). However, after 48 h, the highest
concentration of PG (1 mg/mL) reduced the number of cells compared
to the control. These results indicate that the addition of salmon PG
does not aﬀect endothelial cell viability and growth for 24 h, but a high
concentration of PG slightly reduced cell viability at longer culture
times.
CSPG extensively inhibits the adhesion of various cells to ECM
proteins [24]. Therefore, we examined the eﬀect of salmon PG on the
adhesion of endothelial cells to ﬁbronectin. PG was used to coat non-
coated dish (plastic) and ﬁbronectin-coated dishes. PG inhibited the
adhesion of endothelial cells to the plastic surface and ﬁbronectin in a
concentration-dependent manner (Fig. 1B). These results indicate that
salmon PG has anti-adhesive activity against endothelial cells as seen
for other CSPGs.
3.2. Eﬀect of salmon PG on endothelial tube formation
To examine whether CSPGs inhibit angiogenesis, we evaluated the
eﬀect of salmon PG on in vitro tube formation. The endothelial cells
were cultured on BME from an Engelbreth-Holm-Swarm mouse and
formed a capillary-like structure after 16–18 h of incubation under
serum-free condition (Fig. 2A, 0 mg/mL). Media containing > 0.5 mg/
mL salmon PG signiﬁcantly decreased both the length and number of
the capillary-like structures (Fig. 2) in a concentration-dependent
manner (Fig. 2B). These results suggest that salmon PG inhibits in
vitro endothelial tube formation.
3.3. Eﬀect of salmon PG in the chick CAM assay
We next investigated the eﬀect of salmon PG in the chick CAM
assay as an in vivo angiogenesis model. Application of salmon PG
inhibited the formation of blood vessels in the CAM in a dose-
dependent manner (Fig. 3). At 80 μg/ring, PG reduced the vessel area
by approximately 40% compared to the control (Fig. 3E). These results
suggest that salmon PG also inhibits in vivo CAM angiogenesis.
3.4. GAG is the active component for the anti-angiogenic activity of
salmon PG
Most functions of PGs are derived from their attached GAGs, but
the core protein is functional in some cases [1]. Therefore, we clariﬁed
which component in PG is essential for its anti-angiogenic activity. The
protein components in salmon PG were digested by protease. To
inactivate the enzyme, the reaction mixture was boiled; boiled PG did
Table 1
TaqMan probes for quantitative PCR and relative gene expression levels.
Gene TaqMan probe Ct (mean) SD ΔCt
GAPDH Hs02758991_g1 19.0 0.68 0.00
MMP-1 Hs00899658_m1 20.6 0.80 1.61
MMP-2 Hs01548727_m1 22.2 0.34 3.13
MMP-3 Hs00968305_m1 36.3 0.95 17.29
MMP-7 Hs01042796_m1 35.8 0.77 16.78
MMP-9 Hs00957555_m1 35.3 0.89 16.24
MMP-14 Hs01037009_g1 26.3 0.36 7.32
The Ct values for each gene were calculated based on eight individual samples.
ΔCt = Ct (each gene) – Ct (GAPDH)
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Fig. 1. Eﬀect of salmon PG on cell viability and adhesion of endothelial cells. A. EA.hy926 cells were cultured with PG in serum-free media for 24 or 48 h. The viability was measured by
WST-8 assay. The columns show the mean values ± SD (n =3). **p < 0.01 versus control (0 mg/mL) (Student's t-test). B. EA.hy926 cells were cultured on a PG-coated dish (non-coated
plastic surface or ﬁbronectin-coated surface) for 1 h. The number of attached cells was estimated by crystal violet assay. The columns show the mean values ± SD (n =9). **p < 0.01
versus control (0 mg/mL) (Student's t-test).
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not lose its anti-angiogenic activity (Supplemental Fig. 1). The pro-
tease-treated PG retained anti-angiogenic activity (Fig. 4A) similar to
that of untreated PG. Next, the CS chains of salmon PG were removed
using chondroitinase ABC. The chondroitinase ABC-treated PG showed
no inhibitory activity for tube formation (Fig. 4B). Thus, the CS chains
in salmon PG are the active component underlying its anti-angiogenic
activity.
3.5. Comparison with CS from other sources
Our data indicate that the CS chain in salmon PG is responsible for
its anti-angiogenic activity. Since CS is structurally heterogeneous, we
compared the anti-angiogenic activity of salmon PG to that of CS4S
from whale and CS6S from shark to determine what structure of CS
exhibits this activity. CS4S and PG showed higher anti-angiogenic
activity than CS6S, with the inhibitory activity of CS4S similar to that of
salmon PG (Fig. 4C). These results suggest that CS compositions are
essential for anti-angiogenic activity.
3.6. Eﬀects of salmon PG on MMP expression
MMPs play important roles in angiogenesis. PGs are known to
suppress the expression of MMP-2 and MMP-9 in vitro [25,26].
Therefore, we examined the expression level of MMPs in endothelial
cells treated with salmon PG. Under normal conditions, EA.hy926 cells
expressed relatively high levels of MMP-1, -2, and -14 mRNA and far
lower levels of MMP-3, -7, and -9 (Table 1). After 24 h of incubation
with PG, the expression of MMP-1 and -2 mRNA was reduced by 15–
20%, and that of MMP-14 was reduced slightly (Fig. 5A). In addition,
gelatin zymography showed that the level of MMP-2 was signiﬁcantly
reduced by PG treatment; the 64–68 kDa intermediate form of MMP-2
was abundant, with less of the pro-from (72 kDa) and fully-activated
form (62 kDa) observed, as reported previously (Fig. 5B) [27,28]. PG
treatment signiﬁcantly reduced the amount of the intermediate form
and did not increase the amount of the pro- or fully-activated form,
suggesting that PG reduced the total amount and not the activation of
MMP-2 (Fig. 5B, C). These results suggest that salmon PG inhibits the
expression of MMPs, which contributes to its anti-angiogenic activity.
4. Discussion
The mechanisms underlying avascularity in cartilage remain un-
clear. Normal human cartilage is avascular, whereas OA cartilage loses
its avascularity. The avascularity of OA cartilage has been associated
with PGs and their GAGs [4,29]. CSPG, the major PG in cartilage, is
thought to inhibit vascularization. Angiogenesis involves basement
membrane degradation, endothelial cell proliferation, migration, and
tube formation, which are important targets for anti-angiogenic
therapy. A previous study showed that human invertebrate disc
aggrecan inhibits endothelial cell adhesion and migration [5].
However, it is still unclear whether CSPG inhibits tube formation.
The mechanisms underlying inhibition of angiogenesis by CSPG are
unclear, although CS in salmon PG was essential for the anti-
angiogenic activity (Fig. 4B). CSPG is also a well-known inhibitor of
axon regeneration [2,3]. Inhibition of focal adhesion kinase (FAK)
phosphorylation in integrin signaling is one of the inhibitory mechan-
isms by which CSPG inhibits axonal regeneration [30]. This inhibition
depends on CS in CSPG because chondroitinase pretreatment abol-
ished the inhibition. FAK signaling is also important for angiogenesis
[31]. Thus, inhibition of angiogenesis by CSPG might also occur
through inhibition of FAK phosphorylation by the CS chain.
Furthermore, the core protein could be involved in angiogenesis. It
has been reported that Lumican, a KSPG, inhibits angiogenesis by
reducing MMP-14 expression [25]. This anti-angiogenic activity of
Lumican depends on direct binding between the core protein and the
α2β1 integrin [32]. Herein, chondroitinase ABC-treated PG did not
inhibit tube formation (Fig. 4B), suggesting that the core protein of
salmon aggrecan has no anti-angiogenic activity. However, acetic acid-
extracted salmon nasal PG lacks the C-terminal G3 domain of the core
protein, as we reported previously [12]. Therefore, the function of the
intact aggrecan core protein requires further evaluation.
In previous reports, administrations of CS had both pro- and anti-
angiogenic eﬀects [6,7], although endogenous CS in endothelial cells is
essential for angiogenesis [8]. The concentrations of CS/CSPG used in
this study and others [6] are quite higher than the amount of
endogenous CS in the endothelial cells. Therefore, such a large amount
of CS, as present in the cartilage environment, would have an inhibitory
eﬀect against angiogenesis. However, high concentrations of CS also
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show pro-angiogenic activity [7], indicating that the composition of CS
is also important. CS is a linear, non-branching sugar chain that
comprises a disaccharide repeat of glucuronic acid (GlcUA) and N-
acetylgalactosamine (GalNAc). GlcUA and GalNAc are modiﬁed with
O-sulfation at C-2 and C-4 and/or C-6, respectively [2,3]. Our previous
and present data indicate that salmon PG contains approximately 21–
27% ΔDi-4S and 58–63% ΔDi-6S [12]. For comparison, the composi-
tion of whale CS4S is 70–75% ΔDi-4S and 20–23% ΔDi-6S, and that of
shark CS6S is 13–18% ΔDi-4S and 75–80% ΔDi-6S [33]. Accordingly,
the CS composition in salmon PG is closer to that of shark CS6S than to
that of whale CS4S. However, salmon PG and CS4S showed similar
anti-angiogenic activity, whereas CS6S showed much lower activity
(Fig. 4C). There are two possible reasons for this conﬂict between CS
structure and activity. First, the PG form (core protein with GAG)
might be more eﬀective than CS alone. Our results indicate that salmon
PG decreases adhesion of endothelial cells (Fig. 1B). Although CS is the
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main contributor to the anti-adhesive activity of CSPG, CS alone has no
inhibitory activity [24]. Indeed, shark cartilage CS was shown to have
no inhibitory eﬀect on either cell attachment or spreading of endothe-
lial cells, whereas shark cartilage extract inhibited the adhesion of
endothelial cells [34]. Because the CS structures for salmon and shark
are similar, salmon PG might have a greater eﬀect on inhibition of
adhesion. Therefore, the PG would have more anti-angiogenic activity
than CS6S. The other possibility is that minor disaccharide units in
shark CS6S could have a pro-angiogenic role. Shark CS6S contains 7–
8% ΔDi-SD and 0.5–2.8% ΔDi-SE, whereas whale CS4S and salmon PG
contain much lower contents of ΔDi-SD (1.0–1.8% and 0.6–0.8%,
respectively) and undetectable levels of ΔDi-SE[12,35]. These ΔDi-SD
and ΔDi-SE units in shark CS6S might promote pro-angiogenic factors
like heparin/HSPG. For example, ΔDi-SD and ΔDi-SE units have a high
or moderate aﬃnity for ﬁbroblast growth factor family proteins [36].
Further investigations are needed to determine the relationship
between CS structures and their role in angiogenesis.
The reduction of MMP expression by PG contributed to inhibition
of angiogenesis. Interestingly, PG fractions from shark cartilage have
inhibitory activity for MMP-2 and MMP-9, but CS6S from shark
cartilage shows no signiﬁcant inhibitory activity against MMP-2 and
MMP-9 [26]. These data suggest that the protein component in PG or
the PG form is important for inhibition of MMP expression. In this
study, protease-treated PG still showed anti-angiogenic activity,
whereas the chondroitinase ABC-treated PG did not (Fig. 4B).
Because the protease-treated PG comprises GAG and small remaining
peptides, this semi-PG form might be essential for the reduction of
MMP expression. In fact, protein is necessary for the anti-adhesive
eﬀect of CSPG, but the structure of the protein is not important [24].
Thus, our data suggest that the CS in CSPG is the source of inhibitory
activity, but the PG form could enhance the anti-angiogenic activity.
In conclusion, we show that salmon PG (aggrecan) inhibits not only
endothelial cell adhesion but also tube formation and expression of
MMPs. Our ﬁndings support the anti-angiogenic activity of CSPG and
CS from cartilage.
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